We understand that Mexico has a lot of advantages for holding clinical trials, including the large population, access to specialized patient populations, higher patient retention rates…
In Conversation
Mr. Chadim, after Astellas was formed from the merger between Yamanouchi and Fujisawa, it became your job to lead its Czech subsidiary. Tapani Sura, your colleague…
You took over BOMI as President and CEO only last year. Could you give us a brief background on BOMI Mexico and yourself? BOMI Mexico was…
Let us begin by introducing BACHI, its area of focus and scope of activities? BACHI is a fairly young independent association of the consumer healthcare industry,…
Mr. Tor, prior to joining Stallergenes in 2010, you had been with MSD for nearly two decades. After such a prolonged experience at a major global…
“ Mr. Pfannenschmidt, you have been working for Boehringer Ingelheim for three decades, outlasting several company chairman and witnessing the birth and evolution of the corporate vision… ”
Your grandfather started Chifu a long time ago: the business was registered in 1961. I imagine that the business today is completely different game from the…
Many key figures from the pharmaceutical industry have told us that the hospitals in Taiwan are the keystone to the country’s healthcare industry: the hospitals provide…
Can you provide us with an overview of what the UK market represents for the greater Lonza group? Lonza Biologics is a contract manufacturing organisation employing…
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have…
As the head of Eisai’s European operations, how would you assess the relevance of the European market for Eisai’s global operations when compared to the US…
Under various former names for over five decades, the Agency has undoubtedly played a key role in setting a regulatory framework for Romania’s pharmaceutical market. Over…
